Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).

Autor: Panzuto F; Department of Medical-Surgical Sciences and Translational Medicine, Digestive Disease Unit, Sapienza University of Rome, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy., Albertelli M; Endocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy.; Endocrinology, IRCCS Ospedale Policlinico San Martino, Genova, Italy., De Rimini ML; Nuclear Medicine - PET and Therapy Unit, Dept. of Health Services AORN dei Colli, Naples, Italy., Rizzo FM; Oncology and Breast Unit, Ospedale 'A. Perrino', Brindisi, Italy., Grana CM; Radiometabolic Therapy, Nuclear Medicine Division, IRCCS IEO European Institute of Oncology, Milano, Italy., Cives M; Interdisciplinary Department of Medicine, University of Bari 'Aldo Moro', Bari, Italy., Faggiano A; Unit of Endocrinology, Department of Clinical and Molecular Medicine, ENETS Center of Excellence, Sant'Andrea Hospital, Sapienza University, Via di Grottarossa 1038, Rome, 00189, Italy. antongiulio.faggiano@uniroma1.it., Versari A; Department of Nuclear Medicine, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Reggio Emilia, Italy., Tafuto S; Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS Fondazione 'G. Pascale', Naples, 80131, Italy., Fazio N; Division of Gastrointestinal and Neuroendocrine Tumors Medical Treatment IEO, European Institute of Oncology IRCCS, Milan, Italy., Colao A; Unit of Endocrinology, Diabetology and Andrology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; UNESCO Chair 'Education for Health and Sustainable Development', University of Naples Federico II, Naples, Italy., Scalorbi F; Nuclear Medicine Department, Foundation IRCCS, Istituto Nazionale Tumori, Milan, Italy., Ferone D; Endocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy.; Endocrinology, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Cinieri S; Oncology and Breast Unit, Ospedale 'A. Perrino', Brindisi, Italy., Maccauro M; Nuclear Medicine Department, Foundation IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Jazyk: angličtina
Zdroj: Journal of endocrinological investigation [J Endocrinol Invest] 2024 Oct 12. Date of Electronic Publication: 2024 Oct 12.
DOI: 10.1007/s40618-024-02448-6
Abstrakt: Purpose: This paper outlines the consensus of the Italian Association for Neuroendocrine Tumors(Itanet), the Italian Association of Nuclear Medicine (AIMN), the Italian Society of Endocrinology (SIE), and the Italian Association of Medical Oncology (AIOM) on treating neuroendocrine neoplasms (NENs)with radioligand therapy (RLT).
Methods: A list of 10 questions regarding using RLT ingastroenteropancreatic neuroendocrine tumors (GEP-NETs) was addressed after a careful review of theavailable literature. compiling information from the MEDLINE database, augmented with expert opinionsand recommendations, aligns with the latest scientific research and the author's extensive knowledge.The recommendations are evaluated using the GRADE system, showcasing the level of evidence andthe strength of the recommendations.
Results and Conclusions: Specifically, this paper focuses on thesubcategories of well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) thatexpress somatostatin receptors and are considered suitable for RLT, according to internationalguidelines.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: